Back to resultsBiomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor
Primary Purpose
Childhood Atypical Teratoid/Rhabdoid Tumor, Rhabdoid Tumor of the Kidney
Status
Withdrawn
Phase
Locations
United States
Study Type
Observational
Intervention
Laboratory Biomarker Analysis
Sponsored by
About this trial
This is an observational trial for Childhood Atypical Teratoid/Rhabdoid Tumor
Eligibility Criteria
Inclusion Criteria:
- Samples of RTK and ATRT provided by the Children?s Oncology Group (COG)
Sites / Locations
- Childrens Oncology Group
Arms of the Study
Arm 1
Arm Type
Arm Label
Ancillary-Correlative (gene expression profile, miRNA profile)
Arm Description
Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.
Outcomes
Primary Outcome Measures
Molecular differences between RTK and the ATRT
Secondary Outcome Measures
Full Information
NCT ID
NCT01453465
First Posted
October 1, 2011
Last Updated
August 3, 2018
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
1. Study Identification
Unique Protocol Identification Number
NCT01453465
Brief Title
Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor
Official Title
Gene Expression (GE) and MicroRNA (MIRNA) Expression Profiles of Malignant Rhabdoid Tumors (MRT) of the Kidney (RTK) and Atypical Teratoid Rhabdoid Tumor (ATRT)
Study Type
Observational
2. Study Status
Record Verification Date
October 2017
Overall Recruitment Status
Withdrawn
Study Start Date
November 1, 2011 (Actual)
Primary Completion Date
December 1, 2011 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
4. Oversight
5. Study Description
Brief Summary
This research trial studies biomarkers in samples from patients with rhabdoid tumor of the kidney and atypical teratoid rhabdoid tumor. Studying biomarkers of tissue samples from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.
Detailed Description
PRIMARY OBJECTIVES:
I. To determine if there are molecular differences between rhabdoid tumor of the kidney (RTK) and the atypical teratoid rhabdoid tumor (ATRT).
OUTLINE:
Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Childhood Atypical Teratoid/Rhabdoid Tumor, Rhabdoid Tumor of the Kidney
7. Study Design
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ancillary-Correlative (gene expression profile, miRNA profile)
Arm Description
Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.
Intervention Type
Other
Intervention Name(s)
Laboratory Biomarker Analysis
Intervention Description
Correlative studies
Primary Outcome Measure Information:
Title
Molecular differences between RTK and the ATRT
Time Frame
Up to 3 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Samples of RTK and ATRT provided by the Children?s Oncology Group (COG)
Sampling Method
Non-Probability Sample
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Simone Sredni
Organizational Affiliation
Children's Oncology Group
Official's Role
Principal Investigator
Facility Information:
Facility Name
Childrens Oncology Group
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor
We'll reach out to this number within 24 hrs